Business Insider
My Markets Watchlist
Markets
News
Search
Business
Strategy
Economy
Finance
Retail
Advertising
Careers
Media
Real Estate
Small Business
The Better Work Project
Tech
Science
AI
Enterprise
Transportation
Startups
Innovation
Markets
Stocks
Indices
Commodities
Crypto
Currencies
ETFs
Lifestyle
Entertainment
Culture
Travel
Food
Health
Parenting
Reviews
Tech
Streaming
Tickets
Home
Kitchen
Style
Beauty
Gifts
Deals
Politics
Military & Defense
Law
Education
Personal Finance
Banking
Savings
Best Savings Accounts
Raisin Review
Checking Accounts
Best Checking Accounts
Chime Checking Account
SoFi Checking and Saving
Best Money Market Accounts
CDs
Best CD Rates
Best Bank Account Bonuses
Cash Back Debit Cards
Best Banks
CIT Bank Review
UFB Direct Bank
Small Business Banking
Credit Cards
Credit Scores
Credit Monitoring
Best Credit Cards
Best Cash Back Credit Cards
Best Rewards Credit Cards
Best Travel Credit Cards
Best 0% APR Credit Cards
Best Balance Transfer Credit Cards
Best First Credit Cards
Best Business Credit Cards
Discover it Cash Back Credit Card
Chase Sapphire Preferred Credit Card
Investing
Financial Planning
Retirement
Taxes
Loans
Best personal loans
Best debt consolidation loans
Best Loans for Bad Credit
Student Loans
Best Student Loans
Best Student Loan Refinance
Mortgages
Best mortgage lenders
Best mortgage refinance lenders
Best FHA Lenders
Best HELOC Lenders
Insurance
Best Car Insurance
Homeowners Insurance
Best Homeowners Insurance
Best Renters Insurance
Life Insurance
Best Life Insurance
Pet Insurance
Best Pet Insurance
Travel Insurance
Best Travel Insurance
SquareMouth Travel Insurance
Identity Theft Protection
Video
Big Business
Food Wars
So Expensive
Still Standing
Boot Camp
News for ProQR Therapeutics B.V.
GlobeNewswire
2,517d
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
GlobeNewswire
2,524d
ProQR Announces Financial Results for the Second Quarter of 2018
GlobeNewswire
2,531d
ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids
GlobeNewswire
2,551d
ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July
GlobeNewswire
2,565d
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
GlobeNewswire
2,579d
ProQR to Present at the JMP Life Sciences Conference
GlobeNewswire
2,581d
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire
2,589d
ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference
GlobeNewswire
2,601d
ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
GlobeNewswire
2,615d
ProQR Announces Results for the First Quarter of 2018
GlobeNewswire
2,624d
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
GlobeNewswire
2,631d
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
GlobeNewswire
2,643d
ProQR Announces Annual Meeting of Shareholders
GlobeNewswire
2,644d
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
GlobeNewswire
2,651d
ProQR to Present at Two Upcoming Conferences
GlobeNewswire
2,680d
ProQR to Present at Upcoming Investor Conference
GlobeNewswire
2,685d
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
GlobeNewswire
2,686d
ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
GlobeNewswire
2,701d
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
GlobeNewswire
2,707d
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
GlobeNewswire
2,736d
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
GlobeNewswire
2,748d
ProQR Announces Extraordinary General Meeting of Shareholders
GlobeNewswire
2,776d
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
GlobeNewswire
2,784d
ProQR to Present at the Annual Piper Jaffray Healthcare Conference
GlobeNewswire
2,785d
ProQR Announces Results for the Third Quarter of 2017
GlobeNewswire
2,791d
ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
GlobeNewswire
2,792d
ProQR Announces Proposed Public Offering of Ordinary Shares
GlobeNewswire
2,792d
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
GlobeNewswire
2,796d
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
GlobeNewswire
2,805d
ProQR to Present at EuroTIDES Conference
GlobeNewswire
2,810d
ProQR Announces Management Change and Key Promotions
GlobeNewswire
2,812d
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
GlobeNewswire
2,830d
ProQR to Present at the Chardan Inaugural Gene Therapy Conference
GlobeNewswire
2,841d
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
GlobeNewswire
2,845d
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
GlobeNewswire
2,845d
ProQR to Present at Two Investor Conferences in September
GlobeNewswire
2,847d
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
GlobeNewswire
2,854d
ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
Page
Page
Page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
Page
Find News
News
GO
Otomatik - 146.75.116.64
CloudFlare DNS
Türk Telekom DNS
Google DNS
Open DNS
OSZAR »
